Daily Brief Health Care: Remegen , Basilea Pharmaceutica Ag and more

• Remegen’s product revenue fails to cover R&D expenses and its sales profit is negative, which means that RemeGen’s cost control is disappointing, and the main problem is high selling expenses.
• If RemeGen continues to follow the old path, breakeven will be further out of reach. In other words, we don’t think that the A-share placement will materially change the outlook.
• Remegen’s reasonable market value is RMB12-18 billion. If above RMB18 billion, it’s recommended investors take profits in time. If below RMB12 billion, investors could buy and wait for a rebound.

At its recent capital markets day (CMD) and with the support of key opinion leaders, Basilea highlighted the rising need for innovative therapies to address serious fungal and bacterial infections. It continues to make advancements in this specialised segment through the development of opportunistic acquisitions leveraging its anti-infective expertise. Its growth initiatives remain funded through the traction of its commercialised products, Cresemba and Zevtera. FY24 key strategic priorities include the US commercial launch of antibacterial Zevtera and Phase III trial initiation of first-in-class, broad-spectrum antifungal fosmanogepix.